Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00078314" target="_blank" >RIV/65269705:_____/23:00078314 - isvavai.cz</a>

Výsledek na webu

<a href="https://haematologica.org/article/view/haematol.2022.281754" target="_blank" >https://haematologica.org/article/view/haematol.2022.281754</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2022.281754" target="_blank" >10.3324/haematol.2022.281754</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience

Popis výsledku v původním jazyce

Hairy cell leukemia (HCL) is a rare indolent B-cell neoplasm accounting for 2% of leukemias, with an estimated incidence of &lt;1 case per 100,000 population.1 Purine analogs such as cladribine and pentostatin are potent agents in HCL with complete remission (CR) rates approaching 75-90% with monotherapy.2,3 Despite these response rates, there is no evidence of cure and the majority of patients experience recurrence of the disease and require multiple treatments; repeated exposure to purine analogs yields lower response rates and shorter durations of remission.2 Moreover, the distinct, variant subtype of HCL (HCLv) is more resistant to standard purine analogs,4 so the median overall survival from diagnosis of patients with HCLv is 6-9 years compared to &gt;25 years for those with classical HCL.4-6 First-line chemoimmunotherapy, adding rituximab concurrently with or after treatment with a purine analog, improved CR rates with longer remission periods in both HCL and HCLv.5,7,8 However, treatment for &apos;high-risk&apos; patients and those with disease resistant to purine analogs remains challenging. Allogeneic hematopoietic cell transplant (allo-HCT) can potentially produce long-term remission in many diseases, including chronic leukemias; however, evidence to support the use of allo-HCT in refractory/multiple relapsed HCL has been limited to case reports only.9

Název v anglickém jazyce

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience

Popis výsledku anglicky

Hairy cell leukemia (HCL) is a rare indolent B-cell neoplasm accounting for 2% of leukemias, with an estimated incidence of &lt;1 case per 100,000 population.1 Purine analogs such as cladribine and pentostatin are potent agents in HCL with complete remission (CR) rates approaching 75-90% with monotherapy.2,3 Despite these response rates, there is no evidence of cure and the majority of patients experience recurrence of the disease and require multiple treatments; repeated exposure to purine analogs yields lower response rates and shorter durations of remission.2 Moreover, the distinct, variant subtype of HCL (HCLv) is more resistant to standard purine analogs,4 so the median overall survival from diagnosis of patients with HCLv is 6-9 years compared to &gt;25 years for those with classical HCL.4-6 First-line chemoimmunotherapy, adding rituximab concurrently with or after treatment with a purine analog, improved CR rates with longer remission periods in both HCL and HCLv.5,7,8 However, treatment for &apos;high-risk&apos; patients and those with disease resistant to purine analogs remains challenging. Allogeneic hematopoietic cell transplant (allo-HCT) can potentially produce long-term remission in many diseases, including chronic leukemias; however, evidence to support the use of allo-HCT in refractory/multiple relapsed HCL has been limited to case reports only.9

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica

ISSN

0390-6078

e-ISSN

1592-8721

Svazek periodika

108

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

4

Strana od-do

1676-1679

Kód UT WoS článku

001023596100026

EID výsledku v databázi Scopus

2-s2.0-85152879786